Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.46+0.01 (+2.60%)
Close on Nov 18, 2026Market cap $5.85MP/E –Yield –
Aprea Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aprea Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$13.22M. For fiscal 2025 it was -$13.23M. The highest annual figure on record is -$13.23M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.23M | – |
| FY2024 | Dec 31, 2024 | -$14.32M | – |
| FY2023 | Dec 31, 2023 | -$15.47M | – |
| FY2022 | Dec 31, 2022 | -$113.39M | – |
| FY2021 | Dec 31, 2021 | -$37.45M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$98.47M | – |
See a number that looks wrong?